Young Ryul Park1, Jeeyeon Lee1, Jin Hyang Jung1, Wan Wook Kim1, Chan Sub Park1, Ryu Kyung Lee1, Yee Soo Chae2, Soo Jung Lee2, Ji-Young Park3, Jee Young Park3, Ho Yong Park4. 1. Department of Surgery, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. 2. Department of Hemato-oncology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. 3. Department of Pathology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. 4. Department of Surgery, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. Electronic address: phy123@knu.ac.kr.
Abstract
BACKGROUND/ OBJECTIVE: Neoadjuvant chemotherapy (NAC) is a standard treatment for locally advanced breast cancer, especially for HER2-positive or triple negative breast cancer which shows good response to chemotherapy. However, because a result of biomarkers is, occasionally, changed after NAC, the treatment strategy should be differently applied for patients with locally advanced breast cancer. We compared the results of biomarkers before and after NAC to evaluate the association with disease prognosis and oncologic results. METHODS: Fifty-seven patients with locally advanced breast cancer underwent NAC and the immunohistochemical (IHC) staining results were compared between before and after NAC. And the association between oncologic outcomes and biomarkers was analyzed. RESULTS: Negative status of estrogen receptor (ER) was associated with locoregional recurrence and distant metastasis both before and after NAC (p = 0.021, 0.019; p = 0.018, 0.036). And the negative status of progesterone receptor (PR) and triple negative status before neoadjuvant chemotherapy were also associated with death and distant metastasis, respectively. However, the changes of biomarkers after NAC in breast cancer were not directly associated with any oncologic outcomes. CONCLUSION: The absence of ER in breast cancer before and after NAC would be a significant prognostic factor for local recurrence and distant metastasis. Therefore, the absence of ER should be considered as important factor in determining the treatment strategy.
BACKGROUND/ OBJECTIVE: Neoadjuvant chemotherapy (NAC) is a standard treatment for locally advanced breast cancer, especially for HER2-positive or triple negative breast cancer which shows good response to chemotherapy. However, because a result of biomarkers is, occasionally, changed after NAC, the treatment strategy should be differently applied for patients with locally advanced breast cancer. We compared the results of biomarkers before and after NAC to evaluate the association with disease prognosis and oncologic results. METHODS: Fifty-seven patients with locally advanced breast cancer underwent NAC and the immunohistochemical (IHC) staining results were compared between before and after NAC. And the association between oncologic outcomes and biomarkers was analyzed. RESULTS: Negative status of estrogen receptor (ER) was associated with locoregional recurrence and distant metastasis both before and after NAC (p = 0.021, 0.019; p = 0.018, 0.036). And the negative status of progesterone receptor (PR) and triple negative status before neoadjuvant chemotherapy were also associated with death and distant metastasis, respectively. However, the changes of biomarkers after NAC in breast cancer were not directly associated with any oncologic outcomes. CONCLUSION: The absence of ER in breast cancer before and after NAC would be a significant prognostic factor for local recurrence and distant metastasis. Therefore, the absence of ER should be considered as important factor in determining the treatment strategy.
Authors: Hina Dalal; Malin Dahlgren; Sergii Gladchuk; Christian Brueffer; Sofia K Gruvberger-Saal; Lao H Saal Journal: Sci Rep Date: 2022-03-18 Impact factor: 4.379